S. Keren

BRAF Mutant Lung Cancer: Programmed Death Ligand 1 Expression, Tumor Mutational Burden, Microsatellite Instability Status, and Response to Immune Check-Point Inhibitors

Elizabeth Dudnik, Nir Peled, Hovav Nechushtan et al. · Journal of Thoracic Oncology · 2018 · 220 citations · Full text

Medicine, Molecular Genetics, Oncology +14

Statins, aspirin and risk of venous thromboembolic events in breast cancer patients

Ayelet Shai, Hedy S. Rennert, Ofer Lavie et al. · Journal of Thrombosis and Thrombolysis · 2013 · 25 citations

Medicine, Oncology, Pharmacology +14

dNLR-Based Score Predicting Overall Survival Benefit for The Addition of Platinum-Based Chemotherapy to Pembrolizumab in Advanced NSCLC With PD-L1 Tumor Proportion Score ≥50%

Liran Holtzman, Mor Moskovitz, Damien Urban et al. · Clinical Lung Cancer · 2021 · 24 citations

Medicine, Oncology, Pharmacology +16

Efficacy and Safety of BRAF Inhibitors With or Without MEK Inhibitors in BRAF-Mutant Advanced Non–Small-Cell Lung Cancer: Findings From a Real-Life Cohort

Elizabeth Dudnik, Jair Bar, Nir Peled et al. · Clinical Lung Cancer · 2019 · 14 citations

Medicine, Oncology, Pharmacology +13